RT Journal Article
SR Electronic
T1 Real-life experience of ceritinib in crizotinib-pretreated <em>ALK</em><sup>+</sup> advanced non-small cell lung cancer patients
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00058-2017
DO 10.1183/23120541.00058-2017
VO 4
IS 1
A1 Jacques Cadranel
A1 Alexis B. Cortot
A1 Hervé Lena
A1 Bertrand Mennecier
A1 Pascal Do
A1 Eric Dansin
A1 Julien Mazieres
A1 Christos Chouaid
A1 Maurice Perol
A1 Fabrice Barlesi
A1 Gilles Robinet
A1 Sylvie Friard
A1 Luc Thiberville
A1 Clarisse Audigier-Valette
A1 Alain Vergnenegre
A1 Virginie Westeel
A1 Khemaies Slimane
A1 Alexandru Buturuga
A1 Denis Moro-Sibilot
A1 Benjamin Besse
YR 2018
UL http://openres.ersjournals.com/content/4/1/00058-2017.abstract
AB Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK+) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study.The French TAU study included crizotinib-pretreated patients with advanced ALK+ or ROS proto-oncogene 1 positive (ROS1+) tumours. Patients received oral ceritinib (750 mg·day−1 as a starting dose) and best tumour response (as evaluated by the investigator) and safety were reported every 3 months.A total of 242 TAUs were granted from March 12, 2013 to August 05, 2015. Of the 242 patients, 228 had ALK+ NSCLC and 13 had ROS1+ NSCLC. The median age of ALK+ patients (n=214) was 58.5 years, 51.9% were female, 70.8% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1 and 50.0% had brain metastases. Of the 149 efficacy evaluable ALK+ NSCLC patients, 5.4% had a complete response (CR), 47.0% had a partial response (PR) and 22.8% had stable disease (SD). At September 05, 2015, the median duration of ceritinib treatment (n=182) was 3.9 months but 5.5 months for patients (n=71) with a follow-up of ≥12 months. Higher objective response rate (ORR) was observed for patients with ECOG PS 0 to 1 (55.0% versus 42.4%) and those receiving prior crizotinib for &gt;5 months (51.6% versus 36.1%). Treatment-related adverse events (AEs) were reported in 118 of 208 patients (56.7%), the most common being diarrhoea (22.1%) and hepatic toxicity (19.7%).Ceritinib (750 mg·day−1) demonstrated efficacy similar efficacy to ASCEND-1, ASCEND-2 and phase 3 ASCEND-5 trials with manageable safety in crizotinib-pretreated patients with ALK+ NSCLC.Ceritinib (750 mg per day) showed similar efficacy as in clinical trials in crizotinib-pretreated ALK+ NSCLC patients http://ow.ly/8oXe30h27D0